Assay News and Research

RSS

New diagnostic test detects and identifies SARS-CoV-2 virus in less than five minutes

Scientists from Oxford University’s Department of Physics have developed an extremely rapid diagnostic test that detects and identifies viruses in less than five minutes.

16 Oct 2020

Porvair Sciences offers optimized microplates for affinity binding assays

Porvair Sciences new medium and high bind Krystal microplates set a new standard for uniform and reproducible capture of a wide range of biomolecules ready for affinity binding assays such as ELISA's.

From Porvair Sciences Limited 16 Oct 2020

Rapid development of functionally diverse SARS-COV-2 mouse monoclonal antibodies

Now, a recent study published on the preprint server bioRxiv in October 2020 reports the development of a rapid process for generating high-affinity mouse mAbs, and their functional attributes.

16 Oct 2020

New technology precisely diagnoses sickle cell disease in a minute

Researchers at the University of Colorado Boulder and the University of Colorado Anschutz Medical Campus have developed a new way to diagnose diseases of the blood like sickle cell disease with sensitivity and precision and in only one minute.

15 Oct 2020

Capillary blood microsampling could prove a breakthrough in SARS-CoV-2 serosurveillance

As COVID-19 seems to be making a comeback in many areas of the world, including Japan, a new study published on the preprint server medRxiv in October 2020 shows the relevance of microsamples of blood in serosurveillance of this disease.

15 Oct 2020

Rapid SARS‐CoV‐2 IgM‐IgG combined antibody test

A recent study published on the preprint server medRxiv in October 2020 reports a new diagnostic test for SARS-CoV-2 based on the detection of antibodies.

15 Oct 2020

Researchers develop breakthrough blood test for brain tumors

Genetic mutations that promote the growth of the most common type of adult brain tumors can be accurately detected and monitored in blood samples using an enhanced form of liquid biopsy developed by researchers at Massachusetts General Hospital.

14 Oct 2020

Army researchers team up to test alternative ways to measure COVID-19 antibody levels

Researchers with the U.S. Army Futures Command are part of a team that tested alternative ways to measure COVID-19 antibody levels, resulting in a process that is faster, easier and less expensive to use on a large scale.

14 Oct 2020

Researchers use single cell sequencing technology to characterize immune system of COVID-19 patients

In this study, which was published in the journal Frontiers in Immunology on September 30th, researchers used sequencing to characterize the immune system of patients who survive from COVID-19 infection from symptom onset through recovery.

14 Oct 2020

Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells

Axol Bioscience today announced the expansion of its services, with the introduction of array screening for human induced pluripotent stem cells.

From Axol Bioscience Ltd 13 Oct 2020

In vitro BA-LRA can help detect small molecule drugs for drug-induced liver injury

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the publication of research describing the use of HEPATOPAC® cultures with a targeted in vitro assay to identify small molecule drugs with high potential for drug-induced liver injury (DILI).

13 Oct 2020

Study offers a better understanding of protective antibodies induced by coronavirus

As vaccine trials progress and public health officials brace for a rise in COVID-19 cases, understanding how the body defends itself from SARS-CoV-2 infection is essential.

13 Oct 2020

COVID-19 vaccine candidate shows potent immune response

A COVID-19 vaccine candidate that underwent extensive preclinical testing at the University of Alabama at Birmingham this spring and summer shows potent preclinical immune responses -; including several that distinguish it from other COVID-19 vaccine approaches -; according to a preprint deposited in the BioRxiv repository this week.

13 Oct 2020

Elevated plasma ACE2 activity persists months after SARS-CoV-2 infection

Recently, researchers from the University of Melbourne and Immune Therapies Group, Burnet Institute, Melbourne, reported that downregulation of cardiac ACE2 is linked to increased plasma ACE2 activity. This study is summarized in a preprint paper published in medRxiv.

11 Oct 2020

Temporal predictors of SARS-CoV-2 antibodies

Researchers in a recent paper published as a preprint on the preprint medRxiv, study the clinical factors, the laboratory assays to streamline plasma donor selection, and the durability of nAb responses in adults.

11 Oct 2020

New study reports on extremely potent human monoclonal antibodies for SARS-CoV-2

Researchers have recovered and identified the various types of neutralizing antibodies for SARS-CoV-2 from convalescent COVID-19 patients. Of these, they identified three that are extremely potent and could be used to develop treatment therapies.

11 Oct 2020

Fetal brain models could predict neurodevelopmental outcomes of COVID-19 exposure

Researchers in the United States and Sweden have created personalized models of fetal brain microglia to investigate the effects of maternal infection on the developing brain, including infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

11 Oct 2020

Serum antibodies from SARS-CoV patients effectively neutralized SARS-CoV-2 in cultured cells

Antibodies in serum samples collected from patients infected with SARS-CoV during the 2003 outbreak effectively neutralized SARS-CoV-2 infection in cultured cells, according to a new study.

9 Oct 2020

UroCAD assay is better than urine cytology in detecting bladder cancer

Analysis of DNA copy number variants (CNVs) in the cells exfoliated in urine showed better sensitivity and similar specificity in detecting urothelial carcinoma compared with urine cytology.

9 Oct 2020

Mount Sinai to receive more than $7.3 million as part of NCI's new Serological Sciences Network

Researchers from the Icahn School of Medicine at Mount Sinai will receive more than $7.3 million from the National Cancer Institute as part of the NCI's new Serological Sciences Network (SeroNet), one of the largest coordinated national efforts to study immunology and SARS-CoV-2, the virus that causes COVID-19.

8 Oct 2020

Assay News and Research

New diagnostic test detects and identifies SARS-CoV-2 virus in less than five minutes

Porvair Sciences offers optimized microplates for affinity binding assays

Rapid development of functionally diverse SARS-COV-2 mouse monoclonal antibodies

New technology precisely diagnoses sickle cell disease in a minute

Capillary blood microsampling could prove a breakthrough in SARS-CoV-2 serosurveillance

Rapid SARS‐CoV‐2 IgM‐IgG combined antibody test

Researchers develop breakthrough blood test for brain tumors

Army researchers team up to test alternative ways to measure COVID-19 antibody levels

Researchers use single cell sequencing technology to characterize immune system of COVID-19 patients

Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells

In vitro BA-LRA can help detect small molecule drugs for drug-induced liver injury

Study offers a better understanding of protective antibodies induced by coronavirus

COVID-19 vaccine candidate shows potent immune response

Elevated plasma ACE2 activity persists months after SARS-CoV-2 infection

Temporal predictors of SARS-CoV-2 antibodies

New study reports on extremely potent human monoclonal antibodies for SARS-CoV-2

Fetal brain models could predict neurodevelopmental outcomes of COVID-19 exposure

Serum antibodies from SARS-CoV patients effectively neutralized SARS-CoV-2 in cultured cells

UroCAD assay is better than urine cytology in detecting bladder cancer

Mount Sinai to receive more than $7.3 million as part of NCI's new Serological Sciences Network

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News